Corey A Siegel: SARS-CoV-2 Vaccination for Patients with IBD
Access all of the content
We were delighted to talk to Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, NH, US) around the IOIBD consensus statement on SARS-CoV-2 vaccination in patients with IBD.
- What issues were discussed at the consensus meeting of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) regarding the safety and effectiveness of SARS-CoV-2 vaccination in patients with IBD? (0:16)
- What methodology was used to produce the consensus statement? (1:07)
- What were the key recommendations of the IOIBD regarding SARS-CoV-2 vaccination for patients with IBD? (2:17)
- What statement was made around vaccination of pregnant women with IBD? (4:14)
- What are the remaining concerns and how will these be addressed? (5:18)
Disclosures: Consultant/Advisory Board for Abbvie, BMS, Celgene, Lilly, Janssen, Pfizer, Prometheus and Takeda; Speaker for CME activities for Abbvie, Celgene, Janssen, Pfizer and Takeda; Grant support from Crohn’s and Colitis Foundation, Leona M. and Harry B. Helmsley Charitable Trust, Abbvie, Janssen, Pfizer and Takeda.
Support: Interview and filming supported by Touch Medical Media.
Share this Video
Related Videos In Digestive Disorders
LIBERTY-EoE-TREET analysis looking at prior use of topical corticosteroids: Arjan Bredenoord, DDW 2023
The phase 3 LIBERTY-EoE-TREET study (NCT03633617) evaluated the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic oesophagitis. We caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the part C subgroup analysis, which investigated the effect of prior topical corticosteroid use on the efficacy of […]
Dupilumab as a therapeutic option for eosinophilic oesophagitis: Arjan Bredenoord, DDW 2023
Dupilumab is a fully human monoclonal antibody that inhibits the interleukin-4 and interleukin-13 pathways, and has been approved for the treatment of eosinophilic oesophagitis in the USA and Europe. touchIMMUNOLOGY caught up with Prof Arjan Bredenoord (Amsterdam University Medical Center, Amsterdam, the Netherlands) to discuss the burden of eosinophilic oesophagitis, limitations of current therapeutic options, […]
QUASAR: phase 3 study of guselkumab in moderately to severely active ulcerative colitis: Jessica Allegretti, DDW 2023
The QUASAR Phase 3 Induction Study (NCT04033445) investigated the efficacy and safety of the IL-23 p19 subunit antagonist guselkumab in the treatment of moderately to severely active ulcerative colitis. We caught up with Dr Jessica Allegretti (Brigham and Women’s Hospital, Boston, MA, USA), to discuss the aims, design and inclusion criteria of the QUASAR Phase […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!